UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28

Sortiert nach

Severe Scabies: A French Multi-centre Study Involving 95 Patients with Crusted and Profuse Disease and Review of the Literature

Acta dermato-venereologica, 2023-03, Vol.103, p.adv00878-adv00878

2023

Volltextzugriff (PDF)

Potential Role of Vδ2 + γδ T Cells in Regulation of Immune Activation in Primary HIV Infection

Frontiers in immunology, 2017-09, Vol.8, p.1189-1189

2017

Volltextzugriff (PDF)

Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial

The Lancet (British edition), 2021-03, Vol.397 (10280), p.1195-1203

2021

Volltextzugriff (PDF)

γδ T-cell subsets in HIV controllers: potential role of Tγδ17 cells in the regulation of chronic immune activation

AIDS (London), 2019-07, Vol.33 (8), p.1283-1292

2019

Volltextzugriff (PDF)

Steady-State Pharmacokinetics of Amprenavir Coadministered with Ritonavir in Human Immunodeficiency Virus Type 1-Infected Patients

Antimicrobial Agents and Chemotherapy, 2003-01, Vol.47 (1), p.118-123

2003

Volltextzugriff (PDF)

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent

AIDS (London), 2011-06, Vol.25 (10), p.1271-1280

2011

Volltextzugriff (PDF)

Exclusive oral antibiotic treatment for hospitalized community-acquired pneumonia: a post-hoc analysis of a randomized clinical trial

Clinical microbiology and infection, 2024-08, Vol.30 (8), p.1020-1028

2024

Volltextzugriff (PDF)

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study

Journal of antimicrobial chemotherapy, 2017-06, Vol.72 (6), p.1769-1773

2017

Volltextzugriff (PDF)

Pulmonary Cryptococcosis: Localized and Disseminated Infections in 27 Patients with AIDS

Clinical infectious diseases, 1995-09, Vol.21 (3), p.628-633

1995

Volltextzugriff (PDF)

Long-Term Outcome and Treatment Modifications in a Prospective Cohort of Human Immunodeficiency Virus Type 1-Infected Patients on Triple-Drug Antiretroviral Regimens

Clinical infectious diseases, 2000-10, Vol.31 (4), p.987-994

2000

Volltextzugriff (PDF)

Relationship between HIV protease inhibitors and QTc interval duration in HIV‐infected patients: a cross‐sectional study

British journal of clinical pharmacology, 2009-01, Vol.67 (1), p.76-82

2009

Volltextzugriff (PDF)

Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients

AIDS (London), 2010-10, Vol.24 (16), p.2581-2583

2010

Volltextzugriff (PDF)

Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy

Antimicrobial Agents and Chemotherapy, 2009-07, Vol.53 (7), p.2934-2939

2009

Volltextzugriff (PDF)

Efficacy of darunavir despite low plasma trough levels during late pregnancy in an HIV-hepatitis C virus-infected patient

AIDS (London), 2009-09, Vol.23 (14), p.1923-1924

2009

Volltextzugriff (PDF)

Reply to comment on ‘pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients’

AIDS (London), 2011-04, Vol.25 (7), p.1011-1012

2011

Volltextzugriff (PDF)

Efficacy of darunavir despite low plasma trough levels during late pregnancy in an HIV-hepatitis C virus-infected patient

AIDS (London), 2009 (23), p.1923-1930

2009

Volltextzugriff (PDF)

Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA Study)

Antiviral therapy, 2008-01, Vol.13 (2), p.271-279

2008

Volltextzugriff (PDF)

Efficacy of darunavir despite low plasma trough levels during late pregnancy in an HIV-hepatitis C virus-infected patient

AIDS (London, England), 2009, Vol.23 (14), p.1923-1924

2009

Volltextzugriff (PDF)

Switching Between Medicare Advantage And Traditional Medicare Before And After The Onset Of Functional Disability

Health affairs (Millwood, Va.), 2020-05, Vol.39 (5), p.809-818

2020

Volltextzugriff (PDF)

Pharmacokinetic Model of Tenofovir and Emtricitabine and Their Intracellular Metabolites in Patients in the ANRS 134-COPHAR 3 Trial Using Dose Records

Antimicrobial agents and chemotherapy, 2023-05, Vol.67 (5), p.e0233918-e0233918

2023

Volltextzugriff (PDF)

Effect of Adherence as Measured by MEMS, Ritonavir Boosting, and CYP3A5 Genotype on Atazanavir Pharmacokinetics in Treatment-Naive HIV-Infected Patients

Clinical pharmacology and therapeutics, 2012-11, Vol.92 (5), p.575-583

2012

Volltextzugriff (PDF)

HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro

Journal of antimicrobial chemotherapy, 2008-11, Vol.62 (5), p.914-920

2008

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(27)
Berichte
(1)

Sprache

Englisch
(28)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(24)
Science & Technology
(24)
Humans
(21)
Infectious Diseases
(16)
Female
(14)
Male
(13)
Middle Aged
(12)
Adult
(11)
Biological And Medical Sciences
(11)
Hiv Infections - Drug Therapy
(11)
Life Sciences
(11)
Medical Sciences
(11)
Immunology
(10)
Microbiology
(10)
Human Viral Diseases
(9)
Pharmacology. Drug Treatments
(9)
Viral Diseases
(9)
Virology
(9)
Pharmacology & Pharmacy
(8)
Viral Diseases Of The Lymphoid Tissue And The Blood. Aids
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Severe Scabies: A French Multi-centre Study Involving 95 Patients with Crusted and Profuse Disease and Review of the Literature

Potential Role of Vδ2 + γδ T Cells in Regulation of Immune Activation in Primary HIV Infection

Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial

γδ T-cell subsets in HIV controllers: potential role of Tγδ17 cells in the regulation of chronic immune activation

Steady-State Pharmacokinetics of Amprenavir Coadministered with Ritonavir in Human Immunodeficiency Virus Type 1-Infected Patients

Effects of Standard-Dose Prophylactic, High-Dose Prophylactic, and Therapeutic Anticoagulation in Patients With Hypoxemic COVID-19 Pneumonia: The ANTICOVID Randomized Clinical Trial

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent

Exclusive oral antibiotic treatment for hospitalized community-acquired pneumonia: a post-hoc analysis of a randomized clinical trial

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study

Pulmonary Cryptococcosis: Localized and Disseminated Infections in 27 Patients with AIDS

Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial

Long-Term Outcome and Treatment Modifications in a Prospective Cohort of Human Immunodeficiency Virus Type 1-Infected Patients on Triple-Drug Antiretroviral Regimens

Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia: A Secondary Analysis of a Randomized Clinical Trial

Relationship between HIV protease inhibitors and QTc interval duration in HIV‐infected patients: a cross‐sectional study

Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients

Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy

Efficacy of darunavir despite low plasma trough levels during late pregnancy in an HIV-hepatitis C virus-infected patient

Reply to comment on ‘pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients’

Efficacy of darunavir despite low plasma trough levels during late pregnancy in an HIV-hepatitis C virus-infected patient

Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA Study)

Efficacy of darunavir despite low plasma trough levels during late pregnancy in an HIV-hepatitis C virus-infected patient

Switching Between Medicare Advantage And Traditional Medicare Before And After The Onset Of Functional Disability

Pharmacokinetic Model of Tenofovir and Emtricitabine and Their Intracellular Metabolites in Patients in the ANRS 134-COPHAR 3 Trial Using Dose Records

Effect of Adherence as Measured by MEMS, Ritonavir Boosting, and CYP3A5 Genotype on Atazanavir Pharmacokinetics in Treatment-Naive HIV-Infected Patients

HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro

Suchergebnisse filtern